 |
 August 1, 2007 |
|
|
Lexiva vs. Reyataz: Comparable Efficacy
Lexiva or Reyataz, both combined with Norvir, are similar in their effectiveness. A second study suggests that the dose of Norvir currently used to boost Lexiva levels in the bloodstream can be halved without compromising effectiveness. |
|
| |
|
|
|
July 26, 2007 |
|
|
Norvir/Invirase Go Head-to-Head with Kaletra
Early results from a 48-week clinical trial comparing Norvir (ritonavir)-boosted Invirase (saquinavir) to Kaletra (lopinavir plus ritonavir) suggest that both options are working similarly well in patients starting therapy for the first time, although the rate of virologic failure has thus far been higher in the Norvir/Invirase group.
|
|
| |
|
|
|
Starting or Switching: Truvada Outpaces Combivir in Studies
Researchers have reported extended follow-up data from a clinical trial comparing two pairs of nucleoside reverse transcriptase inhibitors (NRTIs), both combined with Sustiva (efavirenz): once-daily Truvada (tenofovir plus lamivudine) plus Emtriva (emtricitabine) versus Combivir (zidovudine plus lamivudine).
|
|
| |
|
|
|
|
|
July 25, 2007 |
|
|
Sustiva Edges Out Celsentri in Treatment Newbies
A clinical trial has found that Pfizer's CCR5-blocking entry inhibitor, Celsentri (maraviroc), when used by patients starting HIV treatment for the first time, appears somewhat inferior to standard-of-care Sustiva (efavirenz).
|
|
| |
|
|
 |
|
July 26, 2007 |
|
|
Is HIV Treatment Actually Reducing Heart Attack Risk?
New study data reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention indicates that HIV treatment—despite its often negative effects on blood lipid levels—may actually reverse artery hardening that can lead to a heart attack or stroke. |
|
| |
|
|
|
July 25, 2007 |
|
|
Simple Test Can Help Prevent Abacavir Allergy
A clinical trial has confirmed that a simple lab test for a human gene can help prevent a serious allergic reaction caused by abacavir, the active ingredient in Ziagen and a component of Epzicom (Kivexa) and Trizivir. |
|
| |
|
|
|
High Risk of Kidney Problems in HIV
There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney.
|
|
| |
|
|
|
July 23, 2007 |
|
|
Crystal Meth Linked to Lower CD4s in Positive People
HIV-positive people using crystal methamphetamine have lower CD4 cell counts than their HIV-positive counterparts who don’t use the drug, according to new data reported at the IAC Conference in Sydney.
|
|
| |
|
|
|
July 23, 2007 |
|
|
Timed Intercourse Plus PrEP for Low-Risk Natural Conception
HIV-negative women who use pre-exposure prophylaxis (PrEP) immediately prior to engaging in carefully timed sexual intercourse with their antiretroviral-treated HIV-positive male partners may further reduce their already low risk of being exposed to the virus.
|
|
| |
|
|
|
July 22, 2007 |
|
|
AIDS Down Under: IAS Conference Begins in Sydney
The IAS Conference on HIV Pathogenesis, Treatment
and Prevention began with calls
for even greater vigilance to ensure universal access to HIV prevention
and treatment, along with an expansion of research to inform and
strengthen the global response to HIV.
|
|
| |
|
|
|
|
|
July 25, 2007 |
|
|
Pipeline Preview: All The New AIDS Drugs Coming Soon
 Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors.
|
|
| |
|
|
|
Simple Test Eliminates Abacavir Risk
 Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
|
|
| |
|
|
|
July 24, 2007 |
|
|
A Positive Papua New Guinean Speaks Out Against Stigma
 Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
|
|
| |
|
|
|
The Latest on Lipo: Advances & Setbacks
 Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV.
|
|
| |
|
|
|
Which HIV Meds Cause Lipoatrophy?
 In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
|
|
| |
|
|
|
Are We Starting Treatment Early Enough?
 In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
|
|
| |
|
|
|
July 22, 2007 |
|
|
Fauci Defends Bush's AIDS Legacy
 Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
|
|
| |
|
|
|
Regan Hofmann talks with Dr. Nancy Padian about PrEP, microbicides, and circumcision, and asks "when can my boyfriend and I stop using condoms."
A videocast interview with Professor Brian Gazzard, an expert on HIV and aging.
